Pliant Therapeutics, Inc. (NASDAQ:PLRX) CFO Keith Lamont Cummings Sells 10,911 Shares

Pliant Therapeutics, Inc. (NASDAQ:PLRX) CFO Keith Lamont Cummings sold 10,911 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $11.56, for a total transaction of $126,131.16. Following the sale, the chief financial officer now directly owns 282,115 shares in the company, valued at $3,261,249.40. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Pliant Therapeutics Stock Up 2.0 %

Shares of PLRX stock opened at $12.75 on Monday. The company has a quick ratio of 16.12, a current ratio of 16.12 and a debt-to-equity ratio of 0.07. The firm’s 50-day moving average is $12.25 and its 200-day moving average is $14.49. Pliant Therapeutics, Inc. has a 52-week low of $10.29 and a 52-week high of $20.23.

Pliant Therapeutics (NASDAQ:PLRX) last announced its quarterly earnings results on Monday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.02). As a group, equities research analysts forecast that Pliant Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PLRX. First Light Asset Management LLC grew its stake in Pliant Therapeutics by 22.4% in the 4th quarter. First Light Asset Management LLC now owns 3,591,776 shares of the company’s stock valued at $65,047,000 after buying an additional 658,516 shares during the last quarter. Capital International Investors grew its stake in Pliant Therapeutics by 50.9% in the 1st quarter. Capital International Investors now owns 1,377,327 shares of the company’s stock valued at $20,522,000 after buying an additional 464,860 shares during the last quarter. Vanguard Group Inc. grew its stake in Pliant Therapeutics by 13.5% in the 1st quarter. Vanguard Group Inc. now owns 3,478,355 shares of the company’s stock valued at $51,827,000 after buying an additional 412,486 shares during the last quarter. Redmile Group LLC grew its stake in Pliant Therapeutics by 14.9% in the 1st quarter. Redmile Group LLC now owns 3,097,220 shares of the company’s stock valued at $46,149,000 after buying an additional 400,572 shares during the last quarter. Finally, Mass General Brigham Inc acquired a new position in Pliant Therapeutics in the 1st quarter valued at about $4,301,000. Institutional investors and hedge funds own 97.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup cut their price target on shares of Pliant Therapeutics from $45.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of Pliant Therapeutics in a research report on Friday, June 7th. Oppenheimer boosted their price target on shares of Pliant Therapeutics from $47.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 7th. Royal Bank of Canada cut their price target on shares of Pliant Therapeutics from $54.00 to $45.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $38.00 price target on shares of Pliant Therapeutics in a research report on Tuesday, May 7th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $45.38.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.